PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-29.38%
Both companies show declining cash positions (-29.38% vs TRVN's -12.39%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-29.38%
Cash + STI yoy ≥ 1.5x TRVN's -12.39%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Similar to TRVN's -100.00%. Walter Schloss would confirm standard short-term asset patterns.
-29.50%
≥ 1.5x TRVN's -10.53%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.38%
≥ 1.5x TRVN's -10.63%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-13.35%
Less than half of TRVN's 112.68%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Higher Short-Term Debt Growth compared to TRVN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both TRVN and the company show zero Deferred Revenue (Current) Growth.
-6.76%
Exceeding 1.5x TRVN's -0.62%. Michael Burry suspects ballooning short-term obligations vs. competitor.
-9.79%
Less than half of TRVN's 54.90%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.79%
Above 1.5x TRVN's -5.13%. Michael Burry sees a potential leverage warning sign.
0.31%
Less than half of TRVN's 236.75%. David Dodd sees fewer share issuances vs. competitor.
-2.40%
Below half TRVN's -13.18%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-68.44%
≥ 1.5x TRVN's -11.04%. David Dodd sees stronger capital base growth than competitor.
-29.38%
≥ 1.5x TRVN's -10.63%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Total Debt Growth compared to TRVN's zero value, indicating worse performance.
28.92%
Above 1.5x TRVN's 12.39%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.